Abbott Laboratories is a global healthcare company with a diverse portfolio in diagnostics, medical devices, nutrition, and pharmaceuticals. On April 22, 2026, the investment firm Daiwa downgraded its rating for Abbott Laboratories to Neutral. At the time of the downgrade, the company's stock price was $92.75.
The downgrade reflects recent market performance, as the stock price has fallen 3.39% to $92.75, hitting a new 52-week low of $92.66. As highlighted by Seeking Alpha, this drop was influenced by lowered earnings per share (EPS) guidance and weakness in the company's Nutrition segment. EPS is a company's profit divided by its number of shares.
Despite the downgrade, some analyses suggest a buying opportunity. The stock is trading at a forward price-to-earnings (P/E) ratio below its five-year average. The forward P/E ratio compares a company's current share price to its expected future earnings, which can help investors assess if a stock is over or undervalued.
The company maintains a strong financial position with $8.5 billion in cash. It also offers a 2.5% dividend yield, which is a cash payment to shareholders. This dividend has increased for over 50 consecutive years, and free cash flow is projected to grow by 40.5% by 2028.
Abbott Laboratories is also reshaping its platform for growth, with the acquisition of Exact Sciences expected to add $3 billion in sales. A Discounted Cash Flow (DCF) analysis by GuruFocus considers Abbott Laboratories fairly valued at $92.78, assuming an 11.6% annual earnings growth rate for the next ten years.
